Literature DB >> 20150758

Neutralization of Clostridium difficile toxin A using antibody combinations.

Stephen J Demarest1, Mangala Hariharan, Marikka Elia, Jared Salbato, Ping Jin, Colin Bird, Jay M Short, Bruce E Kimmel, Michael Dudley, Gary Woodnutt, Geneviève Hansen.   

Abstract

The pathogenicity of Clostridium difficile (C. difficile) is mediated by the release of two toxins, A and B. Both toxins contain large clusters of repeats known as cell wall binding (CWB) domains responsible for binding epithelial cell surfaces. Several murine monoclonal antibodies were generated against the CWB domain of toxin A and screened for their ability to neutralize the toxin individually and in combination. Three antibodies capable of neutralizing toxin A all recognized multiple sites on toxin A, suggesting that the extent of surface coverage may contribute to neutralization. Combination of two noncompeting antibodies, denoted 3358 and 3359, enhanced toxin A neutralization over saturating levels of single antibodies. Antibody 3358 increased the level of detectable CWB domain on the surface of cells, while 3359 inhibited CWB domain cell surface association. These results suggest that antibody combinations that cover a broader epitope space on the CWB repeat domains of toxin A (and potentially toxin B) and utilize multiple mechanisms to reduce toxin internalization may provide enhanced protection against C. difficile-associated diarrhea.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150758      PMCID: PMC2840238          DOI: 10.4161/mabs.2.2.11220

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  49 in total

1.  Monoglucosylation of low-molecular-mass GTP-binding Rho proteins by clostridial cytotoxins.

Authors:  K Aktories; I Just
Journal:  Trends Cell Biol       Date:  1995-12       Impact factor: 20.808

2.  Carbohydrate recognition by Clostridium difficile toxin A.

Authors:  Antonio Greco; Jason G S Ho; Shuang-Jun Lin; Monica M Palcic; Maja Rupnik; Kenneth K-S Ng
Journal:  Nat Struct Mol Biol       Date:  2006-04-16       Impact factor: 15.369

3.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

Authors:  Jason G S Ho; Antonio Greco; Maja Rupnik; Kenneth K-S Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

4.  Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases.

Authors:  C von Eichel-Streiber; M Sauerborn
Journal:  Gene       Date:  1990-11-30       Impact factor: 3.688

5.  Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y.

Authors:  K D Tucker; T D Wilkins
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 6.  Bacterial protein toxins acting on the cell cytoskeleton.

Authors:  G Donelli; C Fiorentini
Journal:  New Microbiol       Date:  1994-10       Impact factor: 2.479

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Active and passive immunization to protect against antibiotic associated caecitis in hamsters.

Authors:  D S Fernie; R O Thomson; I Batty; P D Walker
Journal:  Dev Biol Stand       Date:  1983

9.  Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.

Authors:  Adam Doern; Xianjun Cao; Arlene Sereno; Christopher L Reyes; Angelina Altshuler; Flora Huang; Cathy Hession; Albert Flavier; Michael Favis; Hon Tran; Eric Ailor; Melissa Levesque; Tracey Murphy; Lisa Berquist; Susan Tamraz; Tracey Snipas; Ellen Garber; William S Shestowsky; Rachel Rennard; Christilyn P Graff; Xiufeng Wu; William Snyder; Lindsay Cole; David Gregson; Michael Shields; Steffan N Ho; Mitchell E Reff; Scott M Glaser; Jianying Dong; Stephen J Demarest; Kandasamy Hariharan
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  23 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

2.  Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.

Authors:  Kaushik Dutta; Avanish K Varshney; Matthew C Franklin; Michael Goger; Xiaobo Wang; Bettina C Fries
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

3.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Authors:  Andre J Marozsan; Dangshe Ma; Kirsten A Nagashima; Brian J Kennedy; Yun Kenneth Kang; Robert R Arrigale; Gerald P Donovan; Wells W Magargal; Paul J Maddon; William C Olson
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

Review 4.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

5.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

6.  A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.

Authors:  Natalie G Anosova; Leah E Cole; Lu Li; Jinrong Zhang; Anna M Brown; Sophia Mundle; Jianxin Zhang; Satyajit Ray; Fuqin Ma; Pierre Garrone; Nicola Bertraminelli; Harry Kleanthous; Stephen F Anderson
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

7.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

8.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

9.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

10.  Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies.

Authors:  Siu-Kei Chow; Cameron Smith; Thomas MacCarthy; Mary Ann Pohl; Aviv Bergman; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.